Evidence map›Paper›PMID 27009061›Full record

Trial reportTrials2016

Supporting Treatment Adherence Readiness through Training (START) for patients with HIV on antiretroviral therapy: study protocol for a randomized controlled trial.

Glenn J Wagner, Sebastien Linnemayr, Bonnie Ghosh-Dastidar, Judith S Currier, Risa Hoffman, Stefan Schneider

2 registry-linked trialsOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02329782 nacompletednot on this map

Controlled Evaluation of the Adherence Readiness Program for ART Adherence

TypeinterventionalSponsorRANDRan2015 to 2020Enrolled240ConditionsHIV Medication AdherenceArmsAdherence Readiness Program
NCT03331978 nacompletednot on this mapstarted 2018, after this paper: background citation

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

TypeinterventionalSponsorRANDRan2018 to 2021Enrolled306ConditionsHIV/AIDSArmsRise - Treatment Education
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Primate immunodeficiency virus classification and nomenclature: Review.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Glenn J WagnerRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA. gwagner@rand.org.
Sebastien LinnemayrRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Bonnie Ghosh-DastidarRAND Corporation, 1776 Main Street, Santa Monica, CA, 90407, USA.
Judith S CurrierDepartment of Medicine, UCLA, Los Angeles, CA, USA.
Risa HoffmanDepartment of Medicine, UCLA, Los Angeles, CA, USA.
Stefan SchneiderLong Beach Education and Research Consultants, Long Beach, CA, USA.
RAND Corporation · USSouthern California Institute for Research and Education · US

Funding

Controlled Evaluation of the Adherence Readiness Program for ART AdherenceR01MH104086 · NIMH · RAND CORPORATION · PI WAGNER, GLENN JOHN · 2015 to 2019
$2.8M
NIMH NIH HHS R01 MH104086
6 · The paper itself

Abstract

backgroundFew HIV antiretroviral adherence interventions target patients before they start treatment, assess adherence readiness to determine the timing of treatment initiation, or tailor the amount of adherence support. The Supporting Treatment Adherence Readiness through Training (START) intervention, based on the information-motivation-behavioral skills model of behavior change, is designed to address these gaps with the inclusion of (1) brief pill-taking practice trials for enhancing pretreatment adherence counseling and providing a behavioral criterion for determining adherence readiness and the timing of treatment initiation and (2) a performance-driven dose regulation mechanism to tailor the amount of counseling to the individual needs of the patient and conserve resources. The primary aim of this randomized controlled trial is to examine the effects of START on antiretroviral adherence and HIV virologic suppression. METHODS/

designA sample of 240 patients will be randomized to receive START or usual care at one of two HIV clinics. Primary outcomes will be optimal dose-taking adherence (>85 % prescribed doses taken), as measured with electronic monitoring caps, and undetectable HIV viral load. Secondary outcomes will include dose-timing adherence (>85 % prescribed doses taken on time) and CD4 count. Primary endpoints will be month 6 (short-term effect) and month 24 (to test durability of effect), though electronic monitoring will be continuous and a fully battery of assessments will be administered every 6 months for 24 months. DISCUSSION: If efficacious and cost-effective, START will provide clinicians with a model for assessing patient adherence readiness and helping patients to achieve and sustain readiness and optimal treatment benefits.

trial registrationClinicalTrials.gov identifier NCT02329782 . Registered on 22 December 2014.

Indexed as

CounselingHealth Knowledge, Attitudes, PracticeMedication AdherencePatient Education as TopicAnti-HIV AgentsCaliforniaClinical ProtocolsCost-Benefit AnalysisDrug Administration ScheduleDrug CostsHIV InfectionsHumansMotivationResearch DesignSocial SupportTime FactorsAnti-HIV AgentsAdherenceAntiretroviralHIVInterventionRandomized controlled trialReadiness

Identifiers

PMID27009061
PMCPMC4806419
OpenAlexW2307552648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.